Quick Answer
Testagen is the synthetic tetrapeptide Lys-Glu-Asp-Gly (KEDG), conventionally assigned to the testes. Its peer-reviewed record is very small: in vitro DNA and histone binding work, and chicken studies that describe the same sequence as a pituitary peptide. The testis-specific findings come from one non-peer-reviewed report by the originating group. It is an early, single-group hypothesis with no independent biological replication.
Testagen is one of the short synthetic peptides from Vladimir Khavinson's group in St Petersburg, alongside Epitalon, Livagen and Prostamax. It has one of the thinnest records in the family: a PubMed search for the name returns two papers, one of them about copper corrosion. This article is therefore short, and much of it is about what is missing.
Sequence and identity
Testagen is lysyl-glutamyl-aspartyl-glycine, written Lys-Glu-Asp-Gly or KEDG, with a molecular formula of C17H29N5O9 and a molecular weight of about 447.4 g/mol. A 2011 study co-authored by Khavinson lists testagen as Lys-Glu-Asp-Gly [1], and an unrelated chemistry group in Romania used the same name and sequence in 2025 [2]. Testagen shares Lys-Glu-Asp with Livagen (KEDA) and Prostamax (KEDP) and differs from Epitalon (Ala-Glu-Asp-Gly) at one position. Under the bioregulator model, a single amino acid is what separates a testicular peptide from liver, prostate and pineal ones.
Origin and tissue association
The name points to the testes, and the group's recent reviews call KEDG a regulator of the male reproductive system [3, 4]. We found no primary source describing how the sequence was derived from testicular tissue. The 2022 review gives the label without a citation [4], and the three papers the 2021 review cites for it, on histone binding, cell differentiation and mouse heart gene expression, did not examine reproductive tissue [3].
The literature also contains a conflicting label. Between 2008 and 2013, Kuznik and colleagues at Chita State Medical Academy, long-standing Khavinson collaborators, described Lys-Glu-Asp-Gly as synthesised from the amino acid composition of anterior pituitary extracts [5, 6]. The accurate position is that Testagen is conventionally assigned to the testes and the male reproductive system, on the strength of the originating group's own reports rather than peer-reviewed testicular studies.
Proposed mechanism
The proposal is the general one for the class: a four-residue peptide crosses the cell and nuclear membranes and binds DNA or histones, changing which genes are accessible for transcription. For Testagen, fluorescently labelled peptide entered the nucleus of HeLa cells, a human cervical cancer line, and bound preferentially to synthetic DNA containing CAG sequences [1]. A second study reported binding to wheat histones [7], and a 2023 docking study predicted good binding to the LAT1, LAT2 and PEPT1 transporters, a possible way into cells [8]. None of this work involved testicular cells or showed a change in gene expression.
What the studies actually show
| Model | What was reported | Source |
|---|---|---|
| HeLa cells, synthetic DNA, histones (in vitro) | Nuclear entry; DNA and histone binding | Peer-reviewed [1, 7] |
| Chickens with the pituitary removed | Partial recovery of thyroid hormones and thyroid and thymus structure | Peer-reviewed [5, 6] |
| Computer modelling | Predicted transporter binding | Peer-reviewed [8] |
| Rat testis explants; irradiated male rats | Testis-specific explant growth; partial preservation of fertility | Not peer-reviewed [9] |
| Men aged 54 to 68 | Larger testosterone rise than standard care alone | Not peer-reviewed, no placebo [9] |
The chicken studies, the only peer-reviewed animal work on this sequence that we found, are a pituitary and thyroid model rather than a testicular one [5, 6]. The testis claims come from a 2021 article by Khavinson and Ryzhak on a Russian medicines reference website, not in a peer-reviewed journal [9]. It reports growth of rat testis explants, by about 54% in young and 41% in old animals, with no significant effect on explants of 16 other tissues, and partial preservation of fertility in irradiated male rats. It also describes 48 men aged 54 to 68 with a diagnosis of male climacteric, randomised to standard supportive care with or without a Testagen preparation, and reports a larger rise in blood testosterone in the Testagen group plus before and after improvements in sperm measures. There was no placebo, blinding is not described, the preparation's sequence is not stated, and the methods are too brief to assess.
How strong is the evidence?
Weak. Every biological study we found came from Khavinson's group or its collaborators, and the testicular and human data sit in one Russian-language article outside the journal system. We found no independent replication, no peer-reviewed study in mammalian testicular tissue and no registered clinical trial. The only independent work using the name tested KEDG as a copper corrosion inhibitor [2], which confirms the sequence and nothing about biology. The missing experiment is a direct, independent test of the tissue-specificity claim: KEDG in testicular cells alongside other tissues and control peptides.
Where Testagen fits
For the history of the bioregulator class, the DNA interaction model and how to weigh this literature, see our overview of bioregulator peptides and the Khavinson research. The prostate member of the same Lys-Glu-Asp series is covered in Prostamax: what the research shows.
References
- Fedoreyeva LI, et al. (2011). Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA. Biochemistry (Moscow), 76(11). PubMed 22117547
- Dobriţescu A, et al. (2025). The Inhibitory Effect and Adsorption Properties of Testagen Peptide on Copper Surfaces in Saline Environments: An Experimental and Computational Study. Molecules, 30(15). PubMed 40807317
- Khavinson VK, et al. (2021). Peptide Regulation of Gene Expression: A Systematic Review. Molecules, 26(22). PubMed 34834147
- Khavinson V, et al. (2022). Transport of Biologically Active Ultrashort Peptides Using POT and LAT Carriers. International Journal of Molecular Sciences, 23(14). PubMed 35887081
- Kuznik BI, et al. (2008). Effect of tetrapeptides Lys-Glu-Asp-Gly and Ala-Glu-Asp-Gly on the structure and function of the thyroid gland in neonatally hypophysectomized chickens. Bulletin of Experimental Biology and Medicine, 145(1). PubMed 19024016
- Pateyk AV, et al. (2013). Effect of peptides Lys-Glu-Asp-Gly and Ala-Glu-Asp-Gly on the morphology of the thymus in hypophysectomized young and old birds. Bulletin of Experimental Biology and Medicine, 154(5). PubMed 23658898
- Fedoreyeva LI, et al. (2013). Interaction of short peptides with FITC-labeled wheat histones and their complexes with deoxyribooligonucleotides. Biochemistry (Moscow), 78(2). PubMed 23581987
- Khavinson VK, et al. (2023). Feasibility of Transport of 26 Biologically Active Ultrashort Peptides via LAT and PEPT Family Transporters. Biomolecules, 13(3). PubMed 36979488
- Khavinson VKh, Ryzhak GA. (2021). Clinical and experimental study of the peptide bioregulator Testagen (in Russian). Online article in the RLS medicines encyclopaedia, urology section. Not published in a peer-reviewed journal; no PubMed record.